Fractionated TBI and etoposide (FTBI-VP16) conditioning is effective therapy for patients receiving allogeneic stem cell transplants for ALL. One of the major doselimiting toxicities with this regimen is mucositis although its effect on patients and hospital resources is not well described. To determine the severity of mucositis (WHO grade 3-4) experienced and assess resource utilisation, we compared the non-haematological toxicities of 38 patients receiving FTBI-VP16 with 104 patients receiving CY and TBI (CYTBI). FTBI-VP16 patients were more likely to develop severe mucositis (odds ratio (OR) 6.0 (95% confidence interval (CI) 1.36, 54.42), Po0.01) and its duration was longer (11.5 vs 8 days, Po0.01). Resource utilisation was considerably higher especially in the use and duration of i.v. narcotics and parenteral nutrition, nursing care requirements and plt-transfusion support. Patients receiving FTBI-VP16 conditioning are ideal candidates for new therapies to prevent or reduce the severity of mucositis.
Introduction
Mucositis is one of the most common side effects of myeloablative conditioning. 1 It can induce severe pain, prevent oral intake, result in airway obstruction, increase the risk of infection and possibly initiate or exacerbate acute gastrointestinal GVHD. [2] [3] Factors predisposing to severe mucositis include TBI containing regimens, recipients with a high body mass index and the presence of the methylenetetrahydrofolate reductase 677 TT genotype. [4] [5] Fractionated TBI and high-dose etoposide (FTBI-VP16) conditioning has been reported to prolong disease-free survival in comparison to CY and TBI (CYTBI) in patients with ALL beyond first CR. 6 Mucositis has been the major dose-limiting toxicity of VP16 used as a single agent in patients with advanced malignancy or when added to chemotherapy only conditioning. [7] [8] Although mucositis has been reported as a frequent toxicity after FTBI-VP16, its duration and effect has not been specifically described in patients receiving this regimen with CsA and MTX (CsA-MTX) as GVHD prophylaxis. [9] [10] This is relevant as the addition of MTX to CSA as GVHD prophylaxis increases the risk and severity of mucositis. 11 We investigated the non-haematological toxicities experienced by patients receiving FTBI-VP16 and CSA-MTX as GVHD prophylaxis. We aimed to evaluate the specific contribution of VP16 by comparing the toxicities of this regimen with CYTBI in patients receiving identical GVHD prophylaxis. The study objectives were to document and compare the severity and incidence of mucositis and resource utilisation between the two groups, as well as explore the effect of potential variables predisposing to mucositis.
Patients and methods
Patients were included for analysis if they had received FTBI-VP16 or CYTBI conditioning for an allogeneic BM or PBPC transplant as therapy for acute leukaemia, nonHodgkin lymphoma or CML. Between January 1992 and February 2006, 142 consecutive patients were transplanted, 38 patients received FTBI-VP16 and 104 patients received CYTBI. Data were collected retrospectively from the medical record. A total of 31, otherwise eligible, patients were not included in the analysis as adequate medical records were unavailable; 4 patients had received FTBI-VP16 and 27 CYTBI.
Mucositis grading
For patients before 1999, mucositis was graded according to the NCI-CTC scale (5 out of 38 FTBI-VP16 and 14 out of 104 CYTBI patients) and thereafter the WHO oral-toxicity scale was used. 12 The 19 patients graded according to the NCI-CTC scale had their grading converted to the WHO scale to maintain consistency. Grade 1 and 2 toxicity grading is similar in both scales, whereas a grade 3 and 4 score on the NCI-CTC criteria was consistent with grade 4 toxicity on the WHO scale. The maximum grade and its duration were recorded. Severe mucositis for this study was defined as grade 3 or 4. At least daily oral examination by the physician and/or nursing staff occurred in all patients and in the majority of cases grading of mucositis was noted in the medical record.
Conditioning therapy FTBI-VP16 consisted of FTBI 1320 cGy in 11 fractions of 120 cGy over 4 days (d À7 to d À4) with lung shielding (calculated lung dose of 8 Gy) and a boost to the chest wall and testes in males. Etoposide of 60 mg/kg was given over 4 h on d À3 with hyperhydration and anti-emetic prophylaxis.
CYTBI consisted of CY 60 mg/kg on d À5 and d À4 and TBI 12 Gy, in six fractions of 200 cGy was given on d À3, À2 and À1.
GVHD prophylaxis
All patients received CsA (3 mg/kg i.v.) and MTX at a planned schedule of 15 mg/m 2 d þ 1, 10 mg/m 2 d þ 3, þ 6 and þ 11 without routine folinic-acid rescue. MTX-dose modification or deletion and folinic-acid rescue was given to patients with severe mucositis or other organ toxicity at physician discretion. From October 2000, prophylactic corticosteroid beginning at day 14 was added in most PBPC recipients as per unit policy. 13 
Supportive care
Oral care included use of soft toothbrushes and QID mouthwashes, consisting of normal saline and before 2001, chlorhexidine gluconate 0.2%. Anti-infective prophylaxis varied with time but most frequently consisted of aciclovir 400 mg po 8 h or 250 mg i.v. 8 h and fluconazole 400 mg i.v. or orally once daily. Prophylactic antibacterial antibiotics were given to most patients before 1999, but thereafter were only instigated for the first febrile episode or for any suspected infection.
14 Filgrastim was used at physician discretion for persistent neutropenia and/or severe mucositis.
A morphine infusion was started when topical analgesia failed to control oral mucositis pain, with fentanyl substituted for patients intolerant of morphine. A ketamine infusion was added if pain was poorly controlled and the narcotic dose could not be increased because of drowsiness or nausea. Patients with severe oral and/or gastrointestinal bleeding were transfused to keep the plt count 420 Â 10 9 /l (in the absence of bleeding, plt-transfusion threshold was 10 Â 10 9 /l) and given topical antifibrinolytic therapy with tranexamic acid mouth wash.
Total parenteral nutrition was generally introduced when an adequate oral intake could not be sustained or in some patients with diarrhoea for gut rest. It was weaned over a period of 1-2 days once oral nutrition recommenced.
Data collected and definitions
In order to determine the effect of previous chemotherapy on mucositis severity, the time from most recent induction/ salvage chemotherapy to time to commencement of conditioning was recorded. Most recent chemotherapy was defined as any systemic therapy given within the last 60 days excluding agents such as hydroxyurea, IFN or intrathecal therapy. As epithelial cell-turnover time has been reported to range from a median of 14 days in the buccal mucosa to 24 days in the hard palate, 15 60 days was considered a sufficient time frame to allow for variability among patients. Recent exposure to MTX and VP16 was documented. Patients who had received chemotherapy 60 days earlier or had not received chemotherapy previously were regarded as comparator.
Standard-risk disease was defined as acute leukaemia in first remission or CML-CP1. High-risk disease included leukaemia beyond first remission and all lymphoma.
Grading of acute GVHD was based on established criteria 16 with the first day of onset being recorded. Gastrointestinal GVHD was confirmed on biopsy.
The occurrence of any culture positive bacterial infections and duration of temperatures X38 1C was recorded, together with the use and duration of additional anti-fungal treatments and the occurrence of probable or proven invasive fungal disease, as defined according to published criteria. 17 The use and duration of i.v. narcotics was documented along with the occurrence of significant side effects related to their use, defined as requiring cessation of infusion and increased nurse:patient ratio for patient safety, due to delirium, respiratory depression and hallucinations.
The requirement for an increased intensity of nursing care was defined as either 1:1 nurse:patient ratio in the transplant unit or as an admission to the intensive care unit.
Engraftment was defined by an ANC of more than 0.5 Â 10 9 /l and peripheral plt count of 420 Â 10 9 /l for at least three consecutive days without transfusion.
Data were also collected regarding the use of filgrastim, duration of transplant admission (from day of commencing conditioning to day of discharge), any concomitant grade 3-4 organ dysfunction and any transplant-related death during the first 100 days.
Statistical methods
The primary outcome analysed was the occurrence of severe (grade 3-4) mucositis. Odds ratios to determine the likelihood of developing mucositis were calculated and the relationships between categorical variables were assessed using either w 2 analysis or Fisher's exact test. A secondary analysis examined potential variables, other than the conditioning regimen, which may have influenced the likelihood of developing severe mucositis. These included recipient age and sex, donor and stem cell source, exposure to recent chemotherapy and disease type. A multivariate analysis was carried out using stepwise logistic regression combining these factors, regardless of P-value in univariate analyses, in order to determine if any combination of variables and the conditioning type were associated with severe mucositis.
Odds ratio and 95% confidence interval were also used to describe the relationship between mucositis-related complications and resource utilisation between the two conditioning regimens. 
Results
Patient characteristics are shown in Table 1 . There was a greater proportion of male recipients in the FTBI-VP16 group with a lower median age. The majority of patients with ALL received FTBI-VP16 as this was protocolised as the preferred conditioning therapy for this disease. In addition, a greater proportion of FTBI-VP16 patients had received recent chemotherapy, as previously defined, and this commonly included ALL-based maintenance therapy. Consequently most FTBI-VP16 patients had received MTX previously, although in the majority this was weekly oral maintenance. The CYTBI patients were more likely to have been previously exposed to VP16 as part of induction/ consolidation therapy for AML or salvage therapy for NHL. Other chemotherapy received included cytarabine, VCR and disease-specific combination therapies. Those with no recent exposure to chemotherapy included 7 out of 38 (18%) in the FTBI-VP16 group vs 47 out of 104 (45%) in the CYTBI group. There were 26 patients, all in the CYTBI group who had not received any previous chemotherapy. The predominance of less-than-ideal donors in the CYTBI group reflects the preferred use of this conditioning regimen for this type of donor, other than recipients with a diagnosis of ALL.
Mucositis
As expected, all patients experienced oral mucositis. Severe mucositis (grade 3-4) occurred more frequently in FTBI-VP16 recipients compared with those receiving CYTBI (Table 2a ) with its duration also being longer (Table 2b ). Table 3 illustrates the occurrence of dose reductions of MTX for severe mucositis, incidence of infections, GVHD and resource utilisation between the two groups.
Effect of mucositis
Dose reductions and/or omissions of MTX were more frequent in those receiving FTBI-VP16, primarily due to the severity of the mucositis. In the FTBI-VP16 group there was a marked increase in the duration or occurrence of the following variables; days of fever 4381C, duration of i.v. analgesia and the addition of ketamine, duration of total parenteral nutrition, additional plt transfusions to manage mucosal bleeding, the use of tranexamic mouthwash and additional nursing resources. The use of empiric antifungals and filgrastim, the occurrence of culture positive infections, grade 3-4 organ toxicities and severe acute GVHD were all higher in the FTBI-VP16 recipients, but these differences were not statistically significant.
GVHD
Severe GVHD (grade 3-4) was similar between the two groups ( Table 3 ). The gastrointestinal tract was the most commonly affected organ experienced by both groups. In the FTBI-VP16 group 17 out of 19 (89%) patients with 
Nursing time
Increased nurse:patient ratio or increased surveillance of patients was required more frequently in those receiving FTBI-VP16, predominantly for maintaining patient safety with hallucinations, management of oral bleeding with severe mucositis or due to sepsis. Admissions to intensive care unit were similar between the two groups, 3 out of 38 (8%) for FTBI-VP16 patients vs 10 out of 104 (10%) most commonly for respiratory support.
Engraftment
There were no differences between neutrophil or plt engraftment in the two groups. Overall, FTBI-VP16 and CYTBI patients receiving PBPC-engrafted neutrophils and plts at a median of 16 and 15 days, respectively. FTBI-VP16 patients receiving BM had neutrophil and plt engraftment at a median of 20 and 22 days, respectively, and CYTBI patients at a median of 22 and 23 days.
Additional data
Grade 3 or 4 organ toxicities (other than mucositis) were similar, with 9 out of 38 (24%) of FTBI-VP16 patients experiencing an additional organ toxicity in comparison to 19 out of 104 (18%) of those receiving CYTBI. The main organs affected, in order of frequency were respiratory (pulmonary haemorrhage, pulmonary oedema), cardiac (pericarditis, infarction), liver (veno-occlusive disease) and bladder (haemorrhagic cystitis). TRM within the first 100 days was low with the CYTBI group having 5 deaths (5%) compared with 2 (5%) in the FTBI-VP16 group.
Variables influencing severe mucositis
The relationship between severe mucositis and several pretransplant variables were analysed (Table 4 ). Univariate analysis demonstrated that exposure to FTBI-VP16 conditioning was the only variable strongly associated with developing severe mucositis (Table 4 ). There was a suggestion that patients with ALL and those who had received recent previous chemotherapy were more likely to develop severe mucositis. There was no evidence of an association between severe mucositis and recipient age, sex, donor type or stem cell source. In multivariate analysis using stepwise logistic regression no combination of these variables was associated with severe mucositis. Exposure to FTBI-VP16 remained the only variable strongly associated with severe mucositis.
Discussion
This retrospective study demonstrates that exposure to FTBI-VP16 conditioning induces severe mucositis in the majority of patients. Moreover, when compared with those receiving another common chemoradiation conditioning regimen CYTBI, FTBI-VP16 patients were more likely to develop severe mucositis of longer duration and resource utilisation in this group was considerably higher, especially in use and duration of i.v. narcotics and total parenteral nutrition, increased nursing surveillance and additional plt or other support to manage bleeding. There was some evidence to suggest that FTBI-VP16 recipients were more likely to develop gastrointestinal GVHD possibly as a result of previous mucosal damage or inability to tolerate full-dose MTX or both. Despite this, the duration of hospitalisation and transplant-related mortality was similar between the two groups suggesting that with the appropriate resources and care, patients can be successfully supported through such severe toxicities. We acknowledge that the contribution of VP16 compared with CY to occurrence and severity of mucositis may be confounded by other patient and scheduling variables. First, the TBI dose and schedule was not identical in the two groups and the relationship of chemotherapy to TBI (prior in CYTBI and subsequent in FTBI-VP16) was different. The TBI-dose difference is, however, small and arguably offset by the smaller fraction size and increase in overall time of delivery that is, 12 Gy in 6 fractions over 3 days vs 13.2 Gy in 11 fractions over 4 days. Although data are limited as to the sparing effect of fractionation on oral mucosa, it has been reported to have a sparing effect on damage to the lung, the liver, the kidney and the lens tissue. 18 With regard to the timing of TBI, some studies have suggested that more BM damage occurs when TBI is given first and greater lung toxicities when TBI is given last, 19 but to our knowledge there are limited data regarding the effect of the scheduling of TBI and chemotherapy on the severity of mucositis. Second, there were imbalances in the characteristics of the groups. FTBI-VP16 patients were generally younger and had more sibling donors. They were also more likely to have received recent chemotherapy, particularly MTX, and to have a diagnosis of ALL. There was no evidence in our analysis that age contributed to mucositis severity, although it has been shown elsewhere that older patients may experience more severe mucositis. 4 Donor source also did not appear to contribute to the severity of mucositis in the univariate analysis. There was some evidence that recent chemotherapy and a diagnosis of ALL were associated with more severe mucositis, but this was not statistically significant with FTBI-VP16 remaining the only variable strongly associated with mucositis severity.
As this was a retrospective study, data used were dependent on accurate record keeping in the medical record. Mucositis grading was documented in the notes by the various medical and nursing staff and as a consequence, interobserver variability almost certainly was present. Nevertheless the differences observed in objective variables such as duration of narcotic analgesia and duration of total parenteral nutrition suggest that the mucositis-grading data were representative.
The presence of the methylenetetrahydrofolate reductase genotype has been demonstrated to predispose patients to more severe mucositis. 4 Owing to the lack of available samples, we were unable to evaluate the presence of this genotype in our patient group. Testing patients prospectively for this genotype may be a useful strategy to try and identify those at highest risk.
We have demonstrated that most patients receiving FTBI-VP16 conditioning therapy are at risk of developing severe mucositis and that the effect on resources to support and treat them is considerable. Identifying the optimal approach in patients to reduce mucositis severity and limit secondary toxicities has proved challenging. 20 New agents, such as recombinant human keratinocyte growth factor (palifermin), have demonstrated efficacy in limiting mucositis in the autologous-transplant setting 21 and in nonrandomised studies in allograft recipients. [22] [23] Accordingly, we are at present evaluating the role of palifermin in reducing the severity and duration of mucositis in patients receiving FTBI-VP16 conditioning
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